Beijing Scitop Bio-tech Co., Ltd.
300858.SZ · SHZ
Company research
Beijing Scitop Bio-tech Co., Ltd. (300858.SZ) is a China-based biotechnology company founded in 2003 and listed on the Shenzhen Stock Exchange, specializing in the research, development, production, and sale of probiotic lactic acid bacteria, postbiotics, and microecological preparations. The company offers a broad portfolio of products including edible probiotic items, compound food additives, and animal and plant microecological preparations, serving diverse end markets such as food processing, healthcare, animal husbandry, and agricultural cultivation. Notably, Scitop has established the largest probiotic strain library in China, housing over 7,000 strains with independent intellectual property rights, underpinning its competitive position against both domestic and international peers. Headquartered in Beijing's Huairou District, the company reported revenues of approximately CNY 366 million in 2025, reflecting a year-on-year growth of around 20.85%, driven largely by its rapidly expanding edible probiotic segment.
Research reports
Uses Peter Lynch’s fair value formula to estimate intrinsic value at 1.69 CNY versus a market price of 16.15 CNY, implying roughly 89% downside and concluding the stock is “not a good investment” at current levels. The report emphasizes overvaluation risk and potential capital loss if valuation multiples compress without commensurate earnings growth.
Simply Wall St · May 14, 2026Beijing Scitop Bio-tech (SZSE:300858) – Stock AnalysisProvides a structured fundamental snapshot highlighting strong balance sheet and financial health (6/6 on their health “Snowflake”), but weak scores on valuation, growth, and past performance, with earnings declining and the share price described as highly volatile. The analysis notes a high P/E and P/S relative to earnings and revenue, modest dividend coverage, and mixed long-term return trends, without issuing an explicit buy/sell call.
Huayuan Securities · May 6, 2026科拓生物(300858.SZ)：益生菌收入快增，盈利短期波动Maintains a “buy” rating while noting 2025 revenue grew about 21% year-on-year, driven by fast-expanding food probiotics and triple-digit growth in animal and plant microecological products, even though Q4 2025 and Q1 2026 margins and net profit were temporarily pressured by new factory ramp-up and higher manufacturing costs. The report’s thesis is that new Inner Mongolia probiotic capacity, BC-end expansion, and pipeline development will support strong 2026–2028 profit growth, with key risks including slower-than-expected probiotic penetration, intensified competition, and underperformance of flagship strains.
Huayuan Securities · October 23, 2025科拓生物(300858.SZ)：Q3收入快增，行业高景气度注入成长动能Reviews 2025 year-to-date results showing about 22% revenue growth and mid–high-teens profit growth, with Q3 revenue up roughly 29% and Q3 net profit up more than 25%, supported by strong sector demand and commencement of stable production at the Inner Mongolia probiotic plant. The authors argue that high industry “景气度” (strong cycle), expanding capacity, and dual B2B/B2C growth drivers underpin a positive medium-term outlook, while flagging risks such as weaker-than-expected probiotic adoption, an adverse competitive landscape, and execution risk around new product and capacity ramp-up.
Huayuan Securities · August 1, 2025科拓生物(300858.SZ)：国内益生菌龙头崛起，品类渗透&国产替代双机遇Initial coverage report positioning科拓生物 as an emerging domestic probiotic leader benefiting from category penetration and import substitution, after shifting its business mix toward food probiotics and microecological products and breaking foreign dominance in high-end strains. It projects 2025–2027 net profit CAGRs in the mid-30% range, supports a “buy” rating based on relative valuation versus peers, and highlights upside from weight-management applications, FDA GRAS approval of a core strain, and expansion across B2B and B2C channels, while citing demand, competitive, and R&D risks.